In the phase II ADAPTeR study, in which 15 patients with metastatic ccRCC were treated with nivolumab, with tissue samples obtained from various sites, Au et al. noted that patients who respond to nivolumab not only exhibit expansion of nivolumab-bound CD8+ T cells, but also importantly demonstrate maintenance of tumor-specific T cell expansion12. Here, CD8A is linked to neoplasm.